Spago Nanomedical was founded in 2007 as a subsidiary of Accelerator Nordic, to advance an invention from Linköping University. The patented invention regarded the use of gadolinium-based nanoparticles as a contrast agent for MRI. Gadolinium gives excellent contrast in MRI, and is the foundation of all MRI-contrast agents used clinically today. However, gadolinium has been associated with a serious and non-treatable side effect, Nephrogenic Systemic Fibrosis, in patients with impaired kidney function. The use of gadolinium-containing MRI-contrast agents is therefore sometimes seen as problematic.
In 2011, Spago Nanomedical initiated the development of a novel nanomaterial for MRI-contrast which instead of gadolinium was based on manganese. This material showed high contrast enhancement on MRI and also had tumor selective properties. It is today the patented nanomaterial which is the basis of Spago Nanomedical’s development project SpagoPix.
In 2014, Spago Nanomedical initiated the project Tumorad, in which a nanomaterial is loaded with radioactive isotopes to create a nanomedical product for tumor selective radionuclide therapy.